When you’re investing in growth stocks, especially in the healthcare space, you might be willing to accept a company’s unprofitability for a period of time, provided its revenue is increasing. However, you don’t have to accept that trade-off as a given — some growth stocks, in fact, have already started recording profits, rewarding their investors. And they’re likely to keep doing it tomorrow.
All three companies I’m about to discuss are profitably making products that are substantially better than the mainstream standards in their fields. They’ve already proven that they can grow steadily without dramatically changing their products or business models. Plus, they each have near-term catalysts that will power their growth over the next few years.
Image source: Getty Images.
1. Organogenesis
When a person gets a cut or scrape, an ordinary small bandage usually does the trick. For complex and serious wounds, however, they might be better served by one of the advanced wound care products made by Organogenesis Holdings (NASDAQ:ORGO).
Organogenesis’ PuraPly AM dressing includes antimicrobial features which make it particularly well-suited for wounds that are likely to get infected, like second-degree burns and traumatic injuries. What’s more, the company offers an entire line of similar products, like skin substitutes for advanced wound care, giving clinicians the ability to choose the specific dressing that’s best suited for any given injury.
From 2016 through 2020, Organogenesis’ revenues grew at a compound annual rate of 25%, and its trailing 12-month revenue currently rests at more than $433 million. That’s quite a rapid pace of growth, and the company looks like it’ll be able to sustain it.
Over the next couple of years, Organogenesis plans to roll out a new line of advanced dressings for burn care, which will drive major growth in its revenue. Much like its current products, the company claims that its new burn care dressings will dramatically speed up wound healing in comparison to the most commonly used products.
As long as healthcare systems continue to agree with that assessment, the stock is likely to keep rising.
2. DexCom
For people with diabetes, maintaining control of their blood glucose levels is critical. But the traditional way of measuring those levels involves pricking one’s finger frequently to take samples for a blood glucose meter. DexCom (NASDAQ:DXCM) offers a more convenient and less painful option in the form of its wearable continuous glucose monitors, which are integrated with its tracking software.
Because they measure blood glucose continuously (as the name implies), DexCom’s monitors help patients to analyze trends in their levels, and allow them to achieve superior control compared to finger sticks. The company constantly updates its successful device designs, and the latest iteration will launch before the end of the year, catalyzing fresh revenue growth.
Over the…
Read More: 3 Innovative Growth Stocks That’ll Make You Richer Through 2025